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Background  :  We  investigated  whether  the  presence  of  diabetes  mellitus  (DM)  was  related  to  the  degree  of  the 
anemia  in  predialytic  patients  with  renal  failure  and  what  was  the  most  relevant  factor  for  anemia  in  patients  with 
chronic  kidney  disease  (CKD)  from  DM  (DM-CKD). 
Methods  :  Seventy  seven  patients  (47  predialytic  patients  with  long-term  type  2  DM  (DM-CKD)  and  30  predialytic 
patients  whose  disease  was  due  to  other  causes  (non  DM-CKD))  were  enrolled  in  this  study.  The  blood  hemoglobin 
(Hb)  and  hematocrit,  and  the  creatinine,  ferritin,  vitamin  B12,  folate,  iron,  LDH,  albumin,  hs-CRP,  intact-PTH, 
erythropoietin,  leptin  and  Insulin-like  growth  factor  I  (IGF-1)  levels  were  measured  using  standard  methods.  The 
estimated  GFR  was  calculated  using  the  abbreviated  MDRD  equation.
Results  :  The  two  groups  did  not  significantly  differ  as  to  age,  gender,  the  serum  creatinine  level  and  the 
inflammatory  status.  The  Hb  level  was  significantly  lower  in  the  DM-CKD  patients  than  that  in  the  non  DM-CKD 
patients  (8.5±1.7  g/dL  vs  9.6±1.6  g/dL,  respectively,  p=0.01).  The  Hb  level  was  significantly  lower  in  the  DM-CKD 
patients  who  were  being  treated  with  ACE  inhibitors  (the  DM-ACE  patients)  than  that  in  the  non  DM-CKD  patients  who 
were  being  treated  with  ACE  inhibitors  (the  non  DM-ACE  patients)  (8.5±1.5  g/dL  vs  10.8±1.6  g/dL,  respectively, 
p=0.001).  Multiple  regression  analysis  indicated  that  serum  IGF-1  concentration  was  independently  associated  with  the 
Hb  level  (β=0.425,  p=0.02)  in  the  DM-CKD  patients. 
Conclusions  :  The  Hb  concentration  was  significantly  lower  in  the  DM-CKD  patients  than  that  in  the  non  DM-CKD 
patients.  It  was  independently  associated  with  the  serum  IGF-1  concentration  in  the  DM-CKD  patients.
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INTRODUCTION
Cardiovascular  complications  are  important  factors  that 
contribute  to  the  increased  risk  of  death  for  patients  with  CKD 
(chronic  kidney  disease),  and  especially  for  those  patients  with 
CKD  and  diabetic  nephropathy.  Therefore,  the  combination  of 
diabetes  and  CKD  has  become  a  major  health  problem.  Anemia 
coupled  with  the  presence  of  diabetes  is  thought  to  play  a 
major  role  in  augmenting  the  cardiovascular  risk  profile  of  CKD 
patients
1).  Anemia  appears  at  an  earlier  stage  of  CKD  in 
patients  with  diabetic  nephropathy  than  that  in  patients  without 
diabetes
2).  Furthermore,  Ishimura  and  colleagues
3)  have 
demonstrated  that  for  a  given  level  of  renal  dysfunction,  anemia 
is  more  severe  in  patients  with  type  2  diabetes  than  that  in 
matched,  non-diabetic,  control  patients.  Although  the  serum 
erythropoietin  (EPO)  concentrations  were  within  the  normal 
range  in  both  groups,  the  Hb  concentration  of  anemic  diabetic 
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non-diabetic  renal  disease.  These  findings  led  the  authors  to 
conclude  that  the  presence  of  diabetes  is  an  independent  risk 
factor  for  the  development  of  anemia.  On  the  contrary,  there 
was  a  study  that  diabetes  itself  does  not  have  an  influence  on 
the  development  of  anemia
4). 
Anemia  is  a  serious  and  frequent  complication  of  CKD,  and 
even  in  patients  who  are  not  receiving  dialysis
5).  This  has  been 
thought  to  be  mainly  caused  by  a  relative  or  an  absolute 
deficiency  of  EPO  production  by  the  kidney
6, 7).  Recombinant 
EPO  has  been  useful  for  the  treatment  of  anemia  of  CKD 
patients
8, 9),  but  some  of  these  patients  respond  poorly
10, 11).  The 
anemia  in  such  cases  may  be  due  to  the  short  survival  of  red 
blood  cells  (RBC)
12),  the  presence  of  unknown  inhibitors  of 
erythropoiesis  in  uremia  patients
13),  hyperparathyroidism,  the 
accumulation  of  aluminum  and  a  nutritional  deficiency  such  as 
iron,  vitamin  B12,  and  folate
14)  in  CKD  patients.  Further,  the  data 
from  several  studies  has  indicated  that  factors  other  than  EPO, 
such  as  IGF-1,  can  promote  erythropoiesis  in  vitro
15)  and 
correct  the  anemia  of  chronic  kidney  disease  in  vivo
16).  In 
addition,  recent  data  has  shown  that  the  adipokine  leptin 
influences  the  EPO  sensitivity  in  patients  with  ESRD
17). 
Therefore,  we  investigated  whether  the  presence  of  DM  was 
related  to  the  severity  of  the  anemia  observed  in  the  patients 
with  renal  failure  and  who  were  not  receiving  dialysis,  and  we 
also  determined  what  was  the  most  relevant  factor  for  inducing 
anemia  from  diabetes  in  patients  with  CKD. 
MATERIALS AND METHODS
Seventy  seven  Korean  patients  with  CKD  (41  males  and  36 
females,  aged  29  to  86,  mean  age:  61  years),  and  who  were 
regularly  followed  at  the  outpatient  clinic  of  Chung-Ang 
University  Hospital  were  enrolled  in  this  study  between  March 
2002  and  September  2005.  None  of  them  had  evidence  of 
clinical  gastrointestinal  bleeding  such  as  a  history  of  tarry  stool 
or  a  positive  stool  occult  blood  test,  an  established  infection 
and/or  severe  microinflammation  above  a  5  mg/dL  level  of 
high-sensitivity  C-reactive  protein  (hs-CRP).  None  of  the 
patients  had  received  blood  transfusions  or  recombinant  human 
EPO  therapy  for  anemia.  None  of  the  patients  had  taken  drugs 
that  could  affect  erythropoiesis  (such  as  aluminum-containing 
phosphate  binders  and  immunosuppressive  agents).
The  serum  creatinine  concentration  (Scr)  was  determined  on 
a  multiparameter  analyzer  (Olympus  AU  640;  Olympus  Optical, 
Tokyo,  Japan)  with  using  Jaffe's  method.  We  then  estimated  the 
glomerular  filtration  rate  (GFR)  using  the  abbreviated  MDRD 
equation  (aMDRD)
18).
aMDRD  =  186×Scr
-1.154×age
-0.203×1.212  (×0.742  if  female).
Forty  seven  patients  (28  males  and  19  females)  had  CKD 
that  was  caused  by  long-term  type  2  DM  (mean  age:  62±12 
years,  age  range:  37  to  86  years)  (the  DM-CKD  patients).  The 
remaining  30  CKD  patients  (14  males  and  16  females)  had  CKD 
that  was  due  to  other  causes  (the  non  DM-CKD  patients)  such 
as  chronic  glomerulonephritis  (n=14),  hypertension  (n=10), 
polycystic  kidney  disease  (n=1)  and  renal  disease  of  an 
unknown  cause  (n=5),  according  to  the  clinical  documents  in  the 
medical  records. 
Blood  samples  were  taken  in  the  morning  during  checkups  at 
the  outpatient  clinic.  The  serum  was  frozen  at  -70℃ until  assay. 
We  measured  patients'  blood  Hb  and  hematocrit  (Hct)  using  an 
automatic  blood  cell  counter  (Coulter  STKS,  Coulter  Electronics, 
Hialeah,  FL,  USA),  and  the  chemistry  profiles  such  as  iron,  the 
total  iron  binding  capacity  (TIBC),  the  ferritin,  lactate 
dehydrogenase  (LDH)  and  albumin  levels  were  determined 
using  an  Hitachi  747  automatic  analyzer  (Hitachi,  Tokyo,  Japan). 
Intact  parathyroid  hormone  (i-PTH)  was  measured  using  a 
commercial  immunoradiometric  assay  (Diagnostic  products 
corporation,  Los  Angeles,  CA,  USA)  with  the  normal  range  set 
at  12-72  pg/mL.  hs-CRP  was  measured  using  the  N  high 
sensitivity  CRP  kit  (Dade  Bering,  Marburg,  Germany).
Serum  EPO  was  measured  by  RIA  using  a  commercially 
available  kit  (Diagnostic  Systems  Laboratories,  Webster,  TX, 
USA)  with  rabbit  anti-human  EPO  that  was  purified  from  urine   
and  calibrated  according  to  the  World  Health  Organization  2nd 
International  Reference  guidelines.  The  normal  range  was 
16.6-37.5  mU/mL,  according  to  the  manufacturer's  instructions. 
The  serum  IGF-1  levels  were  also  determined  by  performing 
RIA  with  a  commercially  available  kit  (Nichols  Institute 
Diagnostics,  San  Juan  Capistrano,  CA,  USA),  and  the  kit  used 
an  acid-ethanol  extraction  method  to  dissociate  IGF-1  from  the 
IGF-1  binding  proteins. 
The  normally  distributed  data  was  expressed  as  the  mean±
standard  deviation  (SD)  or  the  mean  standard  error  of  the  mean 
(SEM).  Differences  between  the  two  groups  were  compared  by 
the  unpaired  student  t-test.  The  dats  with  a  skewed  distribution 
was  expressed  as  medians  (and  the  range).  Differences 
between  the  two  groups  were  compared  by  the  Man-Whitney 
test  with  Welch's  correction.  Differences  between  multiple 
groups  were  determined  by  one-way  ANOVA  testing.  Multiple 
regression  analysis  with  a  forward  elimination  procedure  was 
used  to  assess  the  combined  influence  of  the  variables  on  the 
Hb  levels.  The  following  variables  were  used  in  a  model  of  the 
analysis:  age,  gender,  the  GFR  as  expressed  by  the  aMDRD, 
the  presence  of  DM,  the  transferrin  saturation  (TS),  the  ferritin, 
vitamin  B12,  folate,  LDH,  albumin  and  hs-CRP  levels,  the  usage 
of  angiotensin  converting  enzyme  (ACE)  inhibitor  and  the  serum 
EPO,  IGF-1,  leptin  and  i-PTH  levels.  Gender,  the  presence  of 
DM  and  the  usage  of  ACE  inhibitor  were  represented  by 
dummy  variables  (1:  male,  2:  female,  1:  presence,  2:  absence, The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  3,  September  2007 188
DM-CKD non  DM-CKD p  value
Age  (years)
Gender  (M/F)
Serum  creatinine  (mg/dL)
aMDRD  (mL/min/1.73  m
2)
Hemoglobin  (g/dL)
Hematocrit  (%)
Mean  corpuscular  volume  of  red  blood  cell  (fl)
Mean  corpuscular  hemoglobin  (pg)
Corrected  reticulocyte  count  (%)
Transferrin  Saturation  (%)
Ferritin  (ng/mL)
Vitamin  B12  (pg/mL)
Folate  (pg/mL)
LDH  (mg/dL)
Serum  albumin  (g/dL)
hs-CRP  (mg/L)
ACE  inhibitor  (%)
Intact-PTH  (pg/mL)
Serum  erythropoietin  (mU/mL)
Serum  leptin  (mU/mL)
Serum  IGF-1  (ng/mL)
(n=47)
62±12
28/19 
3.7±0.9
20.3±5.5
8.5±1.7
25.2±4.9
87±4
29.8±1.3 
0.91±0.18
26.1±16.4
291±245
1123±582
13.1±5.9
255±98
2.9±0.6
1.6  (0.3-4.0)
58
68.9±55.0
30.3  (3.8-164.1)
16.1  (0.8+65.6)
232±91
(n=30)
60±17
14/16 
4.1±1.1
19.3±5.7
9.6±1.6*
28.6±4.4*
88±4
29.1±1.2 
0.94±0.25
27.4±13.6
162±85*
783±  396*
8.7±6.1*
236±119
3.6±0.4*
1.5  (0.1-4.9)
36*
73.6±50.8
23.6  (5.9-53.4)
10.1  (1.8-20.1)
310±72*
0.58
0.06
0.13
0.50
0.01
0.01
0.49
0.68
0.36
0.77
0.02
0.04
0.02
0.50
0.01
0.21
0.04
0.23
0.29
0.36
0.02
Data  are  means±SDs,  or  medians  (range). 
M,  male;  F,  female;  DM-CKD,  chronic  renal  failure  from  diabetes  mellitus;  non  DM-CKD,  chronic  renal  failure  from  a  disease  other 
than  diabetes  mellitus;  aMDRD,  the  abbreviated  MDRD  equation;  LDH,  lactate  dehydrogenase;  hs-CRP,  high  sensitivity  C-reactive 
protein;  ACE,  angiotensin  converting  enzyme;  PTH,  parathyroid  hormone;  IGF-1,  insulin-like  growth  factor  1. 
*p<0.05  vs.  DM-CKD
Table  1.  Comparison  of  the  clinical  characteristics  between  the  DM‐CKD  and  non  DM‐CKD  patients
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Figure  1.  Hemoglobin  concentration  levels  with  or  without  ACE 
inhibitors.  Abbreviations  are:  DM-ACE  (n=27),  chronic  renal  failure 
due  to  diabetes  mellitus  receiving  ACE  inhibitor  treatment;  non 
DM-ACE  (n=17),  chronic  renal  failure  due  to  a  disease  other  than 
diabetes  mellitus  receiving  ACE  inhibitor  treatment.;  DM-non  ACE 
(n=20),  chronic  renal  failure  due  to  diabetes  mellitus  without  ACE 
inhibitor  treatment;  non  DM-non  ACE  (n=13),  chronic  renal  failure 
due to a disease other than diabetes mellitus without ACE inhibitor 
treatment,  p=0.001  vs.  DM-ACE. 
1:  usage,  2:  non-usage).  Analysis  was  done  using  the  Instat 
version  3.0  Statistical  System. 
RESULTS
Comparison  of  the  parameters  regarding  erythropoiesis 
between  the  DM-CKD  and  non  DM-CKD  patients
The  Hb  concentration  and  Hct  were  significantly  lower  in  the 
DM-CKD  patients  than  those  levels  in  the  non  DM-CKD 
patients  (8.5±1.7  g/dL  vs  9.6±1.6  g/dL,  p=0.01  and  25.2±4.9% 
vs  28.6±4.4%,  p=0.01,  respectively).  The  mean  corpuscular 
volume  and  mean  corpuscular  hemoglobin  level  of  the  RBCs 
were  within  the  normal  range  in  both  the  DM  and  non  DM-CKD 
patients  (87±4  fl  vs  88±4  fl,  p=0.49  and  29.8±1.3  pg  vs  29.1±
1.2  pg,  p=0.68,  respectively),  and  there  were  no  significant 
differences  between  the  groups.  The  serum  ferritin,  vitamin  B12 
and  folate  levels  were  significantly  higher  in  the  DM-CKD 
patients  than  those  in  the  non  DM-CKD  patients  (291±245 
mg/mL  vs  162±85  ng/mL,  p=0.02  and  1123±582  pg/mL  vs  783
±396  pg/mL,  p=0.04  and  13.1±5.9  pg/mL  vs  8.7±6.1  pg/mL, 
p=0.02,  respectively).  The  serum  EPO  levels  were  similar  in  both 
groups  [30.3  (3.8-164.1)  mU/mL  vs  23.6  (5.9-53.4)  mU/mL, Do-Hyoung  Kim,  et  al  :  Risk  factors  for  anemia  in  CKD 189
Variable  
Dependent Independent β p  value
Hemoglobin  level IGF‐1 0.425 0.02
Age
Sex
GFR  (MDRD)
TS
Ferritin
Vitamin  B12
Folate
LDH
albumin
hs‐CRP
ACE  inhibitor
EPO
Leptin 
i-PTH
0.337
0.173
0.275
-0.211
-0.148
-0.205
0.266
-0.239
-0.015
-0.129
-0.022
0.207
0.053
0.063
0.22
0.54
0.27
0.45
0.83
0.46
0.36
0.39
0.96
0.65
0.94
0.48
0.86
0.82
The  following  variables  were  used  in  a  model  of  the  analysis: 
age,  gender,  GFR,  transferrin  saturation  (TS),  the  ferritin,  vitamin 
B12  and  folate,  LDH,  albumin,  hs-CRP  levels,  usage  of  ACE 
inhibitor,  and  the  serum  EPO,  IGF-1,  leptin  and  i-PTH  leves. 
Table 2. Risk factors affecting the hemoglobin levels in DM‐CKD 
patients
p=0.29].  On  the  contrary,  the  serum  IGF-1  levels  were 
significantly  lower  in  the  DM-CKD  patients  than  those  the  non 
DM-CKD  patients  (232±91  mU/mL  vs  310±72  mU/mL, 
respectively,  p=0.02)  (Table  1). 
Comparison  of  Hb  according  to  the  usage  of  ACE 
inhibitors
The  Hb  concentration  was  significantly  lower  in  the  DM-ACE 
patients  than  that  in  the  non  DM-ACE  patients  (8.5±1.5  g/dL 
vs  10.8±1.6  g/dL,  respectively,  p=0.001)  (Figure  1).  There  was 
no  difference  of  the  Hb  concentration  in  the  non  DM-CKD 
patients.
Risk  factors  affecting  the  Hb  levels  in  the  DM-CKD 
patients  and  the  non  DM-CKD  patients
Multiple  regression  analysis  showed  that  serum  IGF-1 
concentration  was  independently  associated  with  the  Hb  level  in 
the  DM-CKD  patients  (β=0.425,  p=0.02)  (Table  2).  However,  the 
serum  IGF-1  concentration  was  not  associated  with  the  Hb 
level  in  the  non  DM-CKD  patients  and  in  all  the  patients 
(DM-CKD  and  non  DM-CKD)  when  they  were  grouped  together 
(data  not  shown).
DISCUSSION
There  have  been  several  reports  that  anemia  appears  at  an 
earlier  stage  of  CKD  in  the  patients  with  diabetic  nephropathy 
than  in  the  CKD  patients  without  diabetes,  and  the  anemia  in 
DM-CKD  patients  becomes  more  severe,  regardless  of  the  type 
of  DM
2, 3).  The  reason  why  anemia  occurs  at  an  earlier  stage  of 
CKD  in  the  patients  with  DM  is  currently  unclear.  A  few 
explanations  have  been  suggested  by  some  authors.  Up  to  90% 
of  EPO  is  produced  by  the  peritubular  fibroblasts  of  the  kidneys. 
Interstitial  damage  has  been  observed  even  at  an  early  stage  in 
patients  with  diabetic  nephropathy.  Further,  the  deterioration  of 
the  renal  function  in  DM-CKD  patients  is  more  progressive 
compared  to  the  non  DM-CKD  patients.  This  results  in  the 
reduction  of  the  renal  interstitium,  which  correlates  well  with 
early  appearance  of  anemia  in  DM-CKD  patients
19, 20).  Hence,  it 
is  possible  that  EPO  deficiency  anemia  may  reflect  the  early 
renal  interstitial  damage  that  occurs  in  patients  with  diabetes. 
Alternatively,  as  the  release  of  EPO  is  modulated  by  the 
sympathetic  nervous  system,  the  coexistence  of  autonomic 
neuropathy  may  be  relevant
21, 22).  EPO  deficiency  anemia  has 
also  been  reported  in  conjunction  with  autonomic  neuropathy  in 
diabetes.  That  is,  many  authors  have  agreed  that  the  etiology  of 
early  and  severe  anemia  in  DM-CKD  patients  is  related  to  the 
relative  deficiency  of  EPO.  On  the  contrary,  another  group  of 
researchers  concluded  that  both  serum  creatinine  and  the 
presence  of  diabetes  are  independent  risk  factors  for  the 
development  of  anemia,  and  this  is  irrespective  of  the  serum 
EPO  concentration
3).  According  to  our  study  that  enrolled 
groups  of  patients  with  similar  renal  function,  there  was  no 
significant  difference  of  the  serum  EPO  concentration  in  both 
groups  despite  the  lower  Hb  concentration  in  the  DM-CKD 
patients. 
There  was  no  evidence  of  chronic  inflammatory  disease  and 
no  clinical  evidence  of  gastrointestinal  occult  bleeding  in  all  the 
patients.  The  mean  corpuscular  volume  and  the  mean 
corpuscular  hemoglobin  in  the  red  blood  cells  were  within  the 
normal  ranges  for  all  the  patients,  suggesting  that  their  anemia 
was  related  to  chronic  renal  failure,  but  it  was  unrelated  to  a 
deficiency  of  iron,  folate  or  vitamin  B12.  In  addition,  it  was 
observed  that  the  DM-CKD  patients  had  higher  levels  of  ferritin, 
vitamin  B12  and  folate.  Metabolic  and  functional  abnormalities  of 
RBCs  have  been  reported  in  DM  patients,  such  as  a  reduction 
in  the  membrane  fluidity  and  a  decrease  in  Na/K  ATPase
23, 24). 
In  those  studies,  this  led  to  an  increase  in  cell  size,  and 
increased  osmotic  fragility  and  hemolysis.  However,  we  could 
not  find  any  hemolytic  evidence  in  that  there  were  no  significant 
differences  of  the  serum  LDH  levels  and  the  corrected 
reticulocyte  counts  between  the  DM-CKD  patients  and  the  non 
DM-CKD  patients.
IGF-1  is  produced  by  the  liver  and  this  is  under  the  control 
of  growth  hormone  (GH),  as  well  as  being  influenced  by  other 
sources,  including  the  kidney
25).  However,  this  process  is 
dependent  on  appropriate  insulin  levels
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consequence  of  insulin  deficiency,  the  patients  with  type  1  DM 
exhibit  abnormalities  of  the  GH/IGF/IGF-binding  protein 
(IGF-BP)  axis  (including  GH  hypersecretion),  reduced  circulating 
levels  of  IGF-1  and  elevated  levels  of  IGFBP-1
27).  The  IGFBPs 
modulate  IGF-1  by  inhibiting  its  activity
26).  Garay-Sevilla  et  al
27) 
have  also  reported  that  the  free  IGF-1  was  lower  in  type  2  DM 
patients  suffering  with  complications  such  as  retinopathy  and 
nephropathy.  In  our  study,  the  serum  IGF-1  level  was 
significantly  lower  in  the  DM-CKD  patients  than  that  in  the  non 
DM-CKD  patients.  In  addition,  multiple  regression  analysis 
indicated  that  the  serum  level  of  IGF-1  independently 
contributed  to  the  Hb  level  in  the  DM-CKD  patients.  A  previous 
in-vitro  study  suggested  an  important  role  for  IGF-1,  as  well  as 
for  EPO,  in  erythropoiesis
28).  Brox  et  al
28)  reported  that  the 
response  to  subtherapeutic  dosages  of  both  EPO  and  IGF-1 
was  comparable  to  the  maximal  response  obtained  with  a  single 
therapeutic  dose  of  EPO  in  CKD  mice.  Shih  et  al
29)  have 
demonstrated  that  the  serum  IGF-1  levels  in  patients  with 
end-stage  renal  disease  (ESRD)  and  erythrocytosis  were 
significantly  increased  as  compared  with  those  levels  in  normal 
subjects  or  ESRD  patients  with  anemia,  and  this  was  despite 
there  being  no  difference  of  the  serum  EPO  level.  Taken 
together,  we  can  suggest  that  the  earlier  and  more  severe 
anemia  in  DM-CKD  patients  is  related  to  their  serum  IGF-1 
concentration.  But,  the  serum  IGF-1  concentration  was  not 
associated  with  the  Hb  level  in  the  non  DM-CKD  patients  and 
all  the  patients  (the  DM-CKD  and  non  DM-CKD  patients).  This 
discrepancy  between  the  DM-CKD  patients  and  the  non 
DM-CKD  patients  can  not  be  explained  from  our  results.  So, 
we  need  to  perform  further  studies  regarding  the  exact  role  of 
IGF-1  in  DM-CKD  patients.
ACE  inhibitors  have  been  reported  to  reduce  the  Hct  levels 
in  a  number  of  clinical  settings,  and  use  of  ACE  inhibitors  and 
the  reduced  HCT  levels  has  even  led  to  an  exacerbation  of 
anemia  among  dialysis  patients  and  renal  transplant 
recipients
30-32).  There  was  a  report  that  IGF-1  seemed  to  play  a 
role  in  the  ACE  inhibitors-related  decrease  of  the  Hct  in  patients 
with  posttransplant  erythrocytosis,  and  this  mainly  occurred  in 
patients  without  any  modification  of  their  EPO  serum  levels
33).  In 
our  results,  the  DM-CKD  patients  receiving  ACE  inhibitors  had 
a  lower  Hb  concentration  compared  to  the  non  DM-CKD 
patients  taking  ACE  inhibitors.  However,  there  was  no  difference 
of  the  serum  IGF-1  levels  in  both  groups  (data  not  shown). 
ACE  inhibitors  have  been  routinely  used  to  decrease  proteinuria 
in  patients  with  diabetic  nephropathy.  So,  the  mechanism  of  the 
low  hemoglobin  concentration  in  the  patients  with  DM-CKD  and 
who  were  taking  ACE  inhibitors  remains  to  be  determined. 
From  our  results,  we  can  conclude  that  the  Hb  concentration 
was  significantly  lower  in  the  DM-CKD  patients,  and  this  was 
independently  associated  with  the  serum  IGF-1  concentration, 
and  especially  in  the  predialysis  patients.  Prospective  and 
multi-center  based  studies  are  needed  to  investigate  the 
effectiveness  of  IGF-1  treatment  in  diabetic  pre-dialysis 
patients.
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